Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
April 11, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
April 08, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, April 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
March 28, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, March 28, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
March 27, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, March 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Reports Fourth Quarter and Full Year 2023 Financial Results
March 06, 2024 16:09 ET
|
Zymeworks Inc.
Reported $456.3 million in cash resources as of December 31, 2023, which when combined with certain anticipated regulatory milestone payments provides projected cash runway into 2H 2027Initiation of...
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate and Multispecific Platforms at the American Association for Cancer Research Annual Meeting
March 05, 2024 16:30 ET
|
Zymeworks Inc.
Five abstracts accepted for poster presentation highlight company’s differentiated antibody-drug conjugate and multispecific antibody clinical product candidatesStrong preclinical activity across...
Zymeworks Announces Participation in Upcoming Investor Conferences
February 27, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks To Host Fourth Quarter and Full Year 2023 Results Conference Call
February 14, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Appointment of Dr. Alessandra Cesano to its Board of Directors
February 08, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...
Zymeworks Announces Participation in Upcoming Investor Conferences
January 31, 2024 06:00 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional...